Cilostazol indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
No edit summary |
||
| Line 5: | Line 5: | ||
==Indications and Usage== | ==Indications and Usage== | ||
PLETAL is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref> | PLETAL is indicated for the reduction of symptoms of [[intermittent claudication]], as indicated by an increased walking distance.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 17:12, 28 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
PLETAL is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.[1]
References
Adapted from the FDA Package Insert.